NCT05773092 2025-09-03
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT02855125 2024-09-19
A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
Taiho Oncology, Inc.
Phase 2 Completed
NCT00652561 2024-09-03
Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Phase 2 Completed
NCT05529355 2022-09-07
Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer
Anhui Chest Hospital
Phase 2 Unknown
NCT03457337 2020-07-10
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
Henan Cancer Hospital
Phase 2 Unknown
NCT04465968 2020-07-10
DEEP_OCEAN
National Cancer Center Hospital East
Phase 3 Not yet recruiting
NCT04274270 2020-03-19
SBRTLCES
Peking University Third Hospital
Phase NA Unknown
NCT03129256 2019-12-10
EASE
Changzhou Cancer Hospital of Soochow University
Phase 2 Completed
NCT02631460 2015-12-16
S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC
Sun Yat-sen University
Phase 2 Unknown
NCT01459185 2014-09-25
A Feasibility Study of Oral Adjuvant Chemotherapy With S-1
Nagasaki University
Phase 2 Completed
NCT02223611 2014-08-22
S1VSNP
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT00874328 2010-10-25
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
National Cancer Center, Korea
Phase 1/2 Unknown